Louis C. Bock
has served as a member of our board of directors since August 2006.
Since August 2014, Mr. Bock has served as a Venture Partner at Santé Ventures, a venture capital firm. From September 1997 to July 2014, he was Managing Director of Scale Venture Partners, a venture capital firm. Previously,
Mr. Bock held various positions in research, project management, business development and sales at Gilead Sciences, Inc., from September 1989 to September 1997. Prior to Gilead, he was a research associate at Genentech, Inc. from November 1987
to September 1989. He currently serves as a director of Orexigen Therapeutics, Inc., a
publicly-traded
biotechnology company, as well as several private companies including Ascenta Therapeutics, Inc. and
Cardiokinetics, Inc. Mr. Bock served as a director for Heat Biologics, Inc., a
publicly-traded
biotechnology company, from September 2013 to April 2016. In addition, Mr. Bock is responsible for Scale
Venture Partners prior investments in Seattle Genetics, Prestwick Pharmaceuticals, Inc. and Somaxon Pharmaceuticals, Inc. Mr. Bock received his B.S. in Biology from California State University, Chico and his M.B.A. from California State
University, San Francisco. Mr. Bocks extensive clinical and leadership experience in the biotechnology and biopharmaceutical industries, including experience in research, project management, business development and sales, and his
membership on other companies boards of directors, including positions on other audit and nominating/corporate governance committees, contributed to our board of directors conclusion that he should serve as a director of our company.
Cam L. Garner
is one of our
co-founders
and has served as chairman of our board of
directors since August 2006. Mr. Garner
co-founded
specialty pharmaceutical companies Cadence Pharmaceuticals, Inc. (acquired by Mallinckrodt plc in March 2014), Somaxon Pharmaceuticals, Inc. (sold to
Pernix Therapeutics in March 2013), Evoke Pharma, Inc., Elevation Pharmaceuticals, Inc. (sold to Sunovion Pharmaceuticals Inc. in 2012), DJ Pharma (sold to Biovail Corporation in 2000), Verus Pharmaceuticals, Inc., Xcel Pharmaceuticals, Inc.
(acquired by Valeant Pharmaceuticals International in 2005), Neurelis, Inc., Meritage Pharma, Inc. (sold to Shire plc in February 2015), and most recently, Kalyra Pharmaceuticals, Inc., OrPro Therapeutics, Inc., Alastin SkinCare and Zavante, Inc. He
previously served as chairman of Cadence from May 2004 until March 2014, and served as chairman of Verus, Elevation and Meritage until their acquisition and Evoke since January 2007. Mr. Garner was Chief Executive Officer of Dura
Pharmaceuticals, Inc. from 1989 to 1995 and its Chairman and Chief Executive Officer from 1995 to 2000, when it was sold to Elan. In addition to Zogenix, Mr. Garner currently serves as Chairman of Evoke Pharma, a
publicly-traded
company, Kalyra Pharamaceuticals, OrPro, Alastin and Zavante, and serves on the Board of Directors of Aegis and Neurelis. Mr. Garner is also
Chairman-elect
and serves on the Executive Committee of UCSD Moores Cancer Center, San Diego. Mr. Garner earned his B.A. in Biology from Virginia Wesleyan College and an M.B.A. from
Baldwin-Wallace
College. As one of our
co-founders
and having served as our chairman since August 2006, Mr. Garners extensive knowledge of our business, history and
culture, his extensive experience as a board member of multiple
publicly-traded
and
privately-held
companies, and expertise in developing, financing and providing strong
executive leadership to numerous biopharmaceutical companies, contributed to our board of directors conclusion that he should serve as a director of our company.
Mark Wiggins
has served as a member of our board of directors since May 2011. Until 2015 Mr. Wiggins was Senior Vice President of
Business Development with Elcelyx Therapeutics, Inc., a biotechnology company. Previously, he served as Chief Business Officer with Mpex Pharmaceuticals, a biopharmaceutical company, until its acquisition by Axcan Pharma, Inc. in 2011. From May 1998
to February 2009, Mr. Wiggins was employed at Biogen Idec, Inc., and its predecessor Idec Pharmaceuticals Corp., biotechnology companies, where he most recently served as Executive Vice President of Business Development. At Idec
Pharmaceuticals, Mr. Wiggins was a member of the management committee for the collaboration with Genentech Inc. on Rituxan
®
. Prior to Biogen Idec, Mr. Wiggins spent fifteen years in
a number of positions of increasing responsibility in marketing, marketing research and business development at Hybridon, Inc.,
Schering-Plough
Corporation (now Merck), Johnson & Johnson and Pfizer,
Inc. Mr. Wiggins business development transaction experience includes closing over 20 licensing deals and several global corporate partnerships and company acquisitions. Mr. Wiggins earned his B.S. degree in Finance from Syracuse
University and his M.B.A. from the University of Arizona. Mr. Wiggins expertise in business development activities and the marketing of pharmaceutical products, as well as his extensive management experience within the biopharmaceutical
industry, contributed to our board of directors conclusion that he should serve as a director of our company.
8